This trial is intended to evaluate the value of circulating tumor cells (CTC), in combination with unenhanced (without injection of contrast media) low dose (to limit the effective radiation dose below 1,5 mSv) chest computed tomography (LDCT) in the screening of Lung cancer (LC). LDCT screening was shown to reduce LC mortality in smokers and ex-smokers, older than 55 years, with a history of more than 30 pack-years. LDCT however shows a close to 30% rate of false positive that require repeat follow-up and also invasive investigations, but also false negatives with metastatic LC being discovered between screening rounds. Migration of circulating tumor cells (CTC) is an early event of carcinogenesis and characterizes aggressive cancers. We recently showed that CTC can be detected with the ISET technique in a population at high risk for LC, i.e. COPD patients before LC was detectable on LDCT. The study will focus on patients at very high risk for lung cancer i.e. smokers and ex-smokers suffering Chronic Obstructive Pulmonary Disease (COPD). The study will enroll 600 participants who will undergo three rounds of screening at one year intervals, each round combining search for CTC on a blood sample and LDCT. Each participant will be followed for at least one year after the last screening round
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
683
Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
CHU d'Amiens
Amiens, France
CHU de Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHRU de Lille
Lille, France
Hospices Civils de Lyon
Lyon, France
Hôpital Nord
Marseille, France
CHU de Montpellier
Montpellier, France
CHU de Nancy
Nancy, France
Hôpital Bichat
Paris, France
Hôpital Cochin
Paris, France
...and 10 more locations
Rate of detection of circulating tumor cells in patients who will have a LC detected during the study
Time frame: 3 years
Rate of detection of CTC in the whole study population
Time frame: once a year for 3 years
Circulating tumor cells
Predictive value of CTC detection for the diagnosis of LC in patients identified as having a pulmonary nodule.
Time frame: once a year for 3 years
Time span between detection of CTC and detection of lung cancer with LDCT and vice versa
Time frame: once a year for 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.